sameAs
Structural basis for antagonism and resistance of bicalutamide in prostate cancerPreclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraceptionCharacterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparationsSelective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized ratsExpanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligandsStudy Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)MicroRNAs are mediators of androgen action in prostate and muscleEffect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulatorsUnexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targetsTip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activationChiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ringA selective androgen receptor modulator for hormonal male contraceptionDiscovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugsInhibitors of tubulin assembly identified through screening a compound library.Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaDevelopment and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.17-β estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor-β.ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female miceSelective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signalingThe selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications.Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents.Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor.Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice.Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene derivatives of medetomidine.Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitorDiscovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingStructural basis for accommodation of nonsteroidal ligands in the androgen receptor
P50
Q24523708-B99B2F10-B118-485C-9057-D19640C8A9FCQ24645334-56704494-F4C7-4A4B-BB63-C2E6EC183B14Q24676629-7E6A7897-4D75-47B3-BA43-044C0B301065Q24676655-019B2920-7E40-4721-B48D-826BAF235C67Q24680340-1B826FEE-4016-45CB-AC2C-43970FAA0C76Q24680373-E798D838-D335-429A-9EC8-435CC3119E0EQ26747940-38633D66-6D9C-46C3-BA59-9837B5F42802Q27317226-B7F141B3-BA95-45EB-83B3-D6CAA74AC5F0Q27652258-5B65E21C-E015-4149-9736-526A5C78DBD7Q27667478-FE49F169-1E85-49DD-A045-3E81A4B1E885Q28251356-D9DE15D3-21E5-4EAE-B132-5ABEEA64CD21Q28371636-94F52F86-4C62-44B1-BA14-2064CD0CA7EFQ28575118-3347B1B6-767D-48E9-A175-751E7AFC693DQ33289718-6BCDB4DC-E193-4356-823B-CBAB8D9FEF84Q33393885-F2C2818D-4A6F-4813-B444-C5F6DF845FB2Q33440318-FEE7592D-6905-4C0B-9106-C795BE715894Q33440533-0DB58461-DC5F-44A9-A05C-9CDD598C5E94Q33576546-777B06C3-0720-42D8-B9AD-72D29E61A76CQ33584903-93E7151E-73C6-4EDC-85B6-9AC9269D0577Q33966915-1076FB63-59CA-499C-8A99-C447CBAD3A78Q34029187-A413FC1E-E995-4720-A9EA-742AFAB8AD3BQ34035236-044B7CCE-07FC-4834-A056-729C1835A28AQ34105493-23048CDC-AD96-43C0-9681-80E36FF7A3DFQ34164900-33DFB242-1214-46F5-86BC-B055E3CBC790Q34165597-14277625-A9C0-4B6B-9D77-C5767EDE7F82Q34179713-38B25072-0E3B-4635-AFBB-6D8AE3096036Q34181302-B4E39EB5-E65E-4F34-9686-F1C13D039C05Q34340804-FA231136-2903-498D-8463-8E30B5A2AF8BQ34382484-6CE6FE53-0C86-4496-8D9D-059632C23E0CQ34389284-B2DF5E42-DAAB-4519-9D1C-DBFE99F4CFFAQ34426686-FFF3636C-9C4A-4E06-91D9-FD65D7A9B7D1Q34497901-868222D5-05BD-46C6-966A-21ECFDBDCD7DQ34503560-5264D4F6-3FA9-47F9-942F-B10312759B14Q34543861-196B727E-C15B-4140-B788-5E30DF537C4CQ34576078-019C2BEC-0F11-43B2-A095-1CD994E718B0Q35080328-85BB1A58-9BB8-4774-A91F-7D8971121B8CQ35264818-6AE37DC5-7336-4735-B06F-3B7918D19AEAQ36087730-D1403BBE-B32B-467C-9A5B-AA21F7EFF763Q36130944-BD2A1BD3-FF08-4463-B386-E8610DC767B3Q36130953-31043D83-16E5-4DA8-849B-9D5F35A328A4
P50
description
onderzoeker
@nl
pharmaceutical researcher
@en
հետազոտող
@hy
name
James T Dalton
@ast
James T Dalton
@en
James T Dalton
@es
James T Dalton
@nl
James T Dalton
@sq
James T. Dalton
@de
James T. Dalton
@fr
James T. Dalton
@pt
type
label
James T Dalton
@ast
James T Dalton
@en
James T Dalton
@es
James T Dalton
@nl
James T Dalton
@sq
James T. Dalton
@de
James T. Dalton
@fr
James T. Dalton
@pt
altLabel
James T. Dalton
@en
James T. Dalton
@es
prefLabel
James T Dalton
@ast
James T Dalton
@en
James T Dalton
@es
James T Dalton
@nl
James T Dalton
@sq
James T. Dalton
@de
James T. Dalton
@fr
James T. Dalton
@pt
P106
P214
P1153
7202788237
P21
P214
P31
P496
0000-0002-3915-7326
P569
1963-01-01T00:00:00Z
P734
P735
P7859
lccn-no2009079346